ACP Issues 3-Tier Menopause Drug Guideline, Drawing Criticism Over Tier-3 NKRA Ranking
Updated
Updated · vajenda.substack.com · Oct 16
ACP Issues 3-Tier Menopause Drug Guideline, Drawing Criticism Over Tier-3 NKRA Ranking
1 articles · Updated · vajenda.substack.com · Oct 16
Summary
The American College of Physicians published its first guideline on menopausal vasomotor symptoms, ranking drug treatments in three tiers intended to guide selection by effectiveness and safety rather than dosing.
Tier 1 puts estrogen with or without progestogen first-line, Tier 2 lists SNRIs such as desvenlafaxine and venlafaxine, and Tier 3 includes SSRIs, gabapentin, and neurokinin receptor antagonists including fezolinetant and elinzanetant.
Critics argue the hierarchy is not transparent because tibolone was excluded for unspecified safety concerns, while conjugated estrogens/bazedoxifene was left out for allegedly insufficient harms data despite FDA approval and trial evidence.
They also say NKRAs were pushed to Tier 3 largely on cost grounds even though ACP rated their evidence moderate certainty—the same as Tier 2 SNRIs—risking confusion between price and clinical effectiveness.
Because insurers and pharmacy benefit managers often use guideline tiers to set coverage and step therapy, the ranking could limit access for women who cannot take estrogen, including some with breast-cancer histories.